Mendelsohn shares Tang Prize for leadership in developing targeted...
Targeted cancer therapy pioneer John Mendelsohn, M.D., researcher and former president of The University of Texas MD Anderson Cancer...
Phase III study shows quizartinib prolongs overall survival for...
A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall...
Researchers find combination can enhance ipilimumab...
Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint...
MD Anderson, Houston Methodist scientists detect new ovarian...
Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription...
Aspen Making Cancer History® Seminar marks 20th anniversary
The University of Texas MD Anderson Cancer Center will host its 20th annual Making Cancer History® seminar in Aspen, 10 a.m.-12 p.m....
PARP inhibitor improves overall response rates in small...
In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center adding the PARP inhibitor...
MD Anderson Therapeutics Discovery team identifies and...
A drug discovered and advanced by The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) and...
MD Anderson and nation’s top cancer centers endorse goal of...
Recognizing that vaccination rates for the human papillomavirus (HPV) remain low across the U.S., particularly in Texas, The...
MD Anderson announces 2018 Andrew Sabin Family Fellows
The University of Texas MD Anderson Cancer Center has named eight researchers to the third annual class of Andrew Sabin Family...
Checkpoint inhibitor shrinks advanced squamous cell skin...
Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced...